The defense giant's stock jumped over 4% following an optimistic sales forecast and a major new agreement to significantly boost production of a key missile defense system for the U.S. military.
Shares of industrial distributor QXO have soared over 70% in the past year, prompting investors to question if the rally has run its course. A deep dive into the valuation metrics, however, suggests the market may still be underestimating the company's cash flow potential.
Western Digital's fiscal Q2 2026 results showcase robust growth, with revenue climbing 25% year-over-year to $3.0 billion. The company credits accelerating AI adoption for driving demand for its high-capacity nearline hard drives and advanced technologies like HAMR and UltraSMR.
Capital Management Corp sold $5.8 million worth of Nexstar Media Group shares, reducing its position in the broadcaster after a year of strong outperformance. The move highlights investor balancing acts amid cyclical advertising headwinds and long-term election cycle potential.
Alliance Resource Partners (ARLP) reported robust fourth-quarter earnings, driven by cost discipline and a resilient coal market. The company provided optimistic 2026 guidance, citing strengthening demand from data centers, industrial growth, and recent winter storms that underscored coal's critical role in grid reliability.
Barrick Gold Corporation is strategically ramping up gold production to capitalize on high prices while simultaneously expanding its copper portfolio as a long-term hedge. The mining giant is also channeling robust profits back to investors through enhanced dividends and buybacks, following a period of stellar stock performance.
Hess Midstream Partners LP (HESM) signals a pivotal shift towards robust free cash flow generation, forecasting a 40% drop in capital expenditures for 2026 as its core system build-out concludes. Despite near-term weather headwinds, strong minimum volume commitments underpin financial targets through 2028.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Allegion's stock has climbed over 30% in the past year, raising questions about its current valuation. A deep dive into the numbers reveals a mixed picture, with key metrics pointing in opposite directions.
Amid a quarter dominated by mega-cap tech and AI fervor, Pzena Investment Management's value-focused fund highlighted discount retailer Dollar General as a key performer, driven by strong earnings that propelled its stock.
CME Group has increased margin requirements for precious metals futures and options following extreme price swings, as daily trading volumes hit record highs. The exchange is also introducing new silver products and enforcing compliance measures, highlighting its dual role as a market facilitator and risk manager during turbulent times.
Despite modest revenue growth and lack of profitability, Cognyte Software (NASDAQ: CGNT) has delivered a remarkable 133% return to shareholders over the past three years, highlighting a stark divergence between financial fundamentals and market optimism.
Footwear giant Deckers Brands announced a 7.1% rise in Q3 FY26 net sales to $1.95 billion, driven by explosive growth from its HOKA running brand and solid gains from UGG, despite a challenging retail environment.
Swiss healthcare group Galenica has delivered robust returns for long-term shareholders, with a total return of 90% over five years, significantly outpacing the broader market. While recent performance has moderated, the stock's journey highlights the value of consistent earnings growth and dividends.
The asset manager declares a $0.03 per share payout, with its dividend yield sitting below industry average as a rising stock price and robust earnings growth paint a complex picture for income-focused investors.
SEI Investments (SEIC) has delivered impressive returns for shareholders over the past five years, but a closer look at its current valuation suggests the stock may have run ahead of its fundamentals. With shares trading near $88, analysis indicates potential overvaluation, prompting investors to weigh future growth against present price.
The industrial sector has outperformed the broader market, buoyed by regulatory shifts. However, not all companies are equally positioned. We analyze one stock with a durable edge and two facing potential headwinds.
The third-quarter earnings season revealed a stark divergence in performance among leading healthcare technology providers. While Omnicell impressed with strong results and a soaring stock, peers like Evolent Health and Astrana Health faced significant market headwinds despite revenue beats.
ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.
Mitsubishi UFJ Financial Group's shares have surged nearly 50% in the past year, capping a remarkable five-year run. As the stock trades near ¥2,751, investors are divided: does the valuation still offer a margin of safety, or has the rally run its course? We delve into the metrics and market sentiment.
